Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roivant
Biotech
Immunovant ends cutaneous lupus program after phase 2 flop
The setback closes off one path to market for the anti-FcRn antibody, but Immunovant continues to pursue other indications.
Nick Paul Taylor
Sep 23, 2026 8:59am
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off
Sep 8, 2026 6:00am
Roivant’s CEO thinks China is a ‘red herring’
Apr 17, 2026 8:35am
Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials
Apr 2, 2026 7:27am
Priovant will move brepocitinib to phase 3 after midstage win
Feb 6, 2026 7:00am
Roivant reports phase 3 autoimmune win for ex-Pfizer asset
Sep 17, 2025 7:00am
